Importance of identification of zygomycetes in the era of newer antifungal agents

Transplant Infectious Disease

Volumn 8, Issue 2, 2006, Pages 122-123

  Bal, A M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; IMMUNOSUPPRESSIVE AGENT; POSACONAZOLE; TACROLIMUS;

ANTIBIOTIC SENSITIVITY; DIAGNOSTIC PROCEDURE; DRUG CONTRAINDICATION; DRUG INDICATION; FUNGUS CULTURE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; GASTROINTESTINAL INFECTION; GENUS; LETTER; MINIMUM INHIBITORY CONCENTRATION; MUCORMYCOSIS; PRIORITY JOURNAL; ZYGOMYCETES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; KIDNEY TRANSPLANTATION; TRIAZOLES; ZYGOMYCOSIS;

EID: 33744797657     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2006.00145.x     Document Type: Letter

References (3)

1. Echo A Hovsepian RV Shen GK. Localized cecal zygomycosis following renal transplantation. Transpl Infect Dis 2005: 7: 68 70.
2. Sun QN Fothergill AW McCarthy DI Rinaldi MG Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002: 46: 1581 1582.
3. Groll AH Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005: 3: 467 487.